DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has granted the Company's U.S. Patent Application No. 18/113,458, which covers the Company's ET-400 product candidate's proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 a ...

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare disea ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. Emerging growth company ☒ (Exa ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to Eton Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. At this time, I would like t ...

Table of Contents UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 37-1858472 (State of incorporation) (I.R.S. Employer Identification Number) 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7278 (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (847) 787-7361 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2023 Earnings Conference Call May 12, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co Operator Good afternoon and welcome to the Eton Pharmaceuticals' First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open the call up for your qu ...

Table of Contents UNITED STATES- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 (Exact name of registrant as specified in its charter) Delaw ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants James Kennedy - Marathon Micro Partners Operator Good afternoon and welcome to the Eton Pharmaceuticals' Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open the call out for your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ 21925 W. Field Parkway, Suite 235 Deer Park, IL 60010-7278 (Address of principal executive offices) (Zip Code) Registrant's telephone number, incl ...